Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 3 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Hormone replacement therapy reduces morbidity in women with Turner Syndrome

02 Feb 2020
Whilst gene therapy has been widely explored in clinical trials and experimental medical studies, its commercial potential has been largely untested.

Overall morbidity and mortality are greater in women with Turner Syndrome (TS), but use of hormone replacement therapy (HRT) may confer benefits to those with 45,X karyotype, particularly on stroke, hypertension and endocrine conditions, suggests a study. However, HRT shows no clear effect on mortality.

Compared with matched controls, women with TS had significantly greater endocrine and cardiovascular mortality and morbidity. Although the risk of mortality was comparable between HRT-treated and nontreated 45,X women, those who received HRT had a significantly reduced use of antihypertensives, antidiabetics and thyroid hormones, as well as significantly lower hospitalization rates for stroke and osteoporotic fractures.

This national cohort study, which followed all TS individuals ever diagnosed in Denmark through 2014, assessed mortality, morbidity and medicinal use in TS and the impact of HRT in 45,X women.

The authors identified 1,156 women diagnosed with TF from 1960 to 2014 from the Danish Cytogenetic Central Registry. Subsequently, Statistics Denmark randomly identified 115,577 age-matched female controls. TS women and controls were linked with person-level data from the National Patient Registry and the Medication Statistics Registry, and were compared in terms of mortality, hospitalizations and medical prescriptions.

Forty-four of the 329 women with 45,X karyotype had never been treated, while the rest had been treated at some point. Those treated were then compared with untreated women regarding their mortality hospitalizations and medical prescriptions.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 3 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.